Open Access. Powered by Scholars. Published by Universities.®

Hematology Commons™

Open Access. Powered by Scholars. Published by Universities.®

1,198 Full-Text Articles 8,061 Authors 439,076 Downloads 93 Institutions

All Articles in Hematology

Faceted Search

1,198 full-text articles. Page 58 of 58.

Proteomic Analysis Of Plasma Exosomes Reveals That Kappa:Lambda Ratio Predicts Severe Acute Graft-Versus-Host Disease, Joseph Alge 2010 Medical University of South Carolina

Proteomic Analysis Of Plasma Exosomes Reveals That Kappa:Lambda Ratio Predicts Severe Acute Graft-Versus-Host Disease, Joseph Alge

MUSC Theses and Dissertations

Background: Acute Graft-Versus-Host disease (acute GVH D) is an often fatal, inflammatory multi-organ disease driven by T cell alloreactivity directed toward host tissues. One of the chief obstacles to improving outcomes of acute GVHD patients is timely diagnosis. Currently, acute GVHD is diagnosed clinically, once the symptoms are fully manifested. However, it is clear that important immunologic events occur prior to the occurrence of symptoms. A biomarker that could predict disease during the asymptomatic period could improve patient outcomes by allowing for earlier intensification of immunosuppressant therapy. Exosomes are an attractive target for acute GVHD biomarker discovery. They contain a …


Successful Use Of Rituximab In Evans Syndrome And Refractory Immune Thrombocytopenic Purpura, Muhammad Kashif, Adnan Qureshi, Salman Naseem Adil, Mohammad Khurshid 2010 Aga Khan University

Successful Use Of Rituximab In Evans Syndrome And Refractory Immune Thrombocytopenic Purpura, Muhammad Kashif, Adnan Qureshi, Salman Naseem Adil, Mohammad Khurshid

Department of Pathology and Laboratory Medicine

Immune cytopenias are mediated by auto-antibodies produced by B-lymphocytes. Conventional treatment of immune-mediated haematological disorders includes immunosuppression with steroids and other immune modulating therapies and in some refractory cases, splenectomy. Response rates to conventional and second-line agents are variable and a proportion of patients require lifelong immunosuppression to maintain the disease in remission. Rituximab, an anti- CD 20 monoclonal antibody has gained widespread acceptance in the management of B-cell malignancies. Additionally, it has been used to treat the disorders associated with autoantibody production. We report herein the successful use of Rituximab in the treatment of two patients with autoimmune cytopenias …


Digital Commons powered by bepress